株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

神経内分泌腫瘍 (NET) :市場考察、疫学、市場予測

Neuroendocrine Tumors (NETs) - Market Insights, Epidemiology and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 745229
出版日 ページ情報 英文 266 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
神経内分泌腫瘍 (NET) :市場考察、疫学、市場予測 Neuroendocrine Tumors (NETs) - Market Insights, Epidemiology and Market Forecast - 2028
出版日: 2019年09月01日 ページ情報: 英文 266 Pages
概要

当レポートでは、神経内分泌腫瘍 (NET) 治療薬市場について調査分析し、疾患の背景、疫学、主要7ヶ国 (米国、ドイツ、スペイン、イタリア、フランス、英国、日本) の市場動向について、体系的な情報を提供しています。

第1章 主な考察

第2章 神経内分泌腫瘍 (NET) :市場概要

第3章 神経内分泌腫瘍 (NET) :疾患の背景と概要

  • イントロダクション
  • NETの分類
  • 原因
  • 危険因子
  • 症状
  • 病態生理
  • 診断

第4章 疫学と患者集団

  • 主な調査結果
  • 主要7ヶ国におけるNETの総発生患者数
  • NETの総発生患者数

第5章 NETの疫学:国別

  • 米国
  • EU5ヶ国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本
  • NETの症例数

第6章 治療アルゴリズム

第7章 アンメットニーズ

第8章 上市薬

  • Afinitor (Everolimus):Novartis
  • Sutent (Sunitinib Malate):Pfizer、など

第9章 新興薬

  • 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen
  • AMG 479: Amgen
  • Anlotinib: Advenchen Laboratories、など

第10章 神経内分泌腫瘍 (NET) :主要7ヶ国の市場分析

  • 主な調査結果
  • 主要7ヶ国におけるNETの市場規模

第11章 国別市場の見通し

第12章 米国:市場の見通し

第13章 EU5ヶ国:市場の見通し

  • ドイツ
  • フランス
  • 英国
  • スペイン
  • イタリア
  • 日本:市場の見通し

第14章 市場促進要因

第15章 市場障壁

第16章 付録

第17章 DelveInsightの機能

第18章 免責事項

第19章 DelveInsightについて

図表

List of Tables

  • Table 1: Secondary causes of nephrotic syndrome
  • Table 2: Systems of nomenclature for NETs
  • Table 3: Grading systems for NETs
  • Table 4: Total Prevalent Population of NETs in the 7MM (2017-2028)
  • Table 5: Total Incident Population of NETs in the 7MM (2017-2028)
  • Table 6: Total Prevalent Cases of NETs in the United States (2017-2028)
  • Table 7: Total Incident Cases of NETs in the United States (2017-2028)
  • Table 8: Diagnosed prevalent cases of NETs in the United States (2017-2028)
  • Table 9: Symptom based classification of NETs in the United States (2017-2028)
  • Table 10: Diagnosed prevalent cases based on Malignancy in the United States (2017-2028)
  • Table 11: Site-specific prevalent cases of NETs in the United States (2017-2028)
  • Table 12: Grade-wise prevalent cases of NETs in the United States (2016-2027)
  • Table 13: Stage-wise prevalent cases of NETs in the United States (2017-2028)
  • Table 14: Total Prevalent Cases of NETs in Germany (2017-2028)
  • Table 15: Total Incident Cases of NETs in Germany (2017-2028)
  • Table 16: Diagnosed prevalent cases of NETs in Germany (2017-2028)
  • Table 17: Symptom based classification of NETs in Germany (2017-2028)
  • Table 18: Diagnosed prevalent cases based on Malignancy in Germany (2017-2028)
  • Table 19: Site-specific prevalent cases of NETs in Germany (2017-2028)
  • Table 20: Grade-wise prevalent cases of NETs in Germany (2017-2028)
  • Table 21: Stage-wise prevalent cases of NETs in Germany (2017-2028)
  • Table 22: Total Prevalent Cases of NETs in France (2017-2028)
  • Table 23: Total Incident Cases of NETs in France (2017-2028)
  • Table 24: Diagnosed prevalent cases of NETs in France (2017-2028)
  • Table 25: Symptom based classification of NETs in France (2017-2028)
  • Table 26: Diagnosed prevalent cases based on Malignancy in France (2017-2028)
  • Table 27: Site-specific prevalent cases of NETs in France (2017-2028)
  • Table 28: Grade-wise prevalent cases of NETs in France (2017-2028)
  • Table 29: Stage-wise prevalent cases of NETs in France (2017-2028)
  • Table 30: Total Prevalent Cases of NETs in Italy (2017-2028)
  • Table 31: Total Incident Cases of NETs in Italy (2017-2028)
  • Table 32: Diagnosed prevalent cases of NETs in Italy (2017-2028)
  • Table 33: Symptom based classification of NETs in Italy (2017-2028)
  • Table 34: Diagnosed prevalent cases based on Malignancy in Italy (2017-2028)
  • Table 35: Site-specific prevalent cases of NETs in Italy (2017-2028)
  • Table 36: Grade-wise prevalent cases of NETs in Italy (2017-2028)
  • Table 37: Stage-wise prevalent cases of NETs in Italy (2017-2028)
  • Table 38: Total Prevalent Cases of NETs in Spain (2017-2028)
  • Table 39: Total Incident Cases of NETs in Spain (2017-2028)
  • Table 40: Diagnosed prevalent cases of NETs in Spain (2017-2028)
  • Table 41: Symptom based classification of NETs in Spain (2017-2028)
  • Table 42: Diagnosed prevalent cases based on Malignancy in Spain (2017-2028)
  • Table 43: Site-specific prevalent cases of NETs in Spain (2017-2028)
  • Table 44: Grade-wise prevalent cases of NETs in Spain (2017-2028)
  • Table 45: Stage-wise prevalent cases of NETs in Spain (2017-2028)
  • Table 46: Total Prevalent Cases of NETs in the UK (2017-2028)
  • Table 47: Total Incident Cases of NETs in the UK (2017-2028)
  • Table 48: Diagnosed prevalent cases of NETs in the UK (2017-2028)
  • Table 49: Symptom based classification of NETs in the UK (2017-2028)
  • Table 50: Diagnosed prevalent cases based on Malignancy in the UK (2017-2028)
  • Table 51: Site-specific prevalent cases of NETs in the UK(2017-2028)
  • Table 52: Grade-wise prevalent cases of NETs in the UK (2017-2028)
  • Table 53: Stage-wise prevalent cases of NETs in the UK (2017-2028)
  • Table 54: Total Prevalent Cases of NETs in Japan (2017-2028)
  • Table 55: Total Incident Cases of NETs in Japan (2017-2028)
  • Table 56: Diagnosed prevalent cases of NETs in Japan (2017-2028)
  • Table 57: Symptom based classification of NETs in Japan (2017-2028)
  • Table 58: Diagnosed prevalent cases based on Malignancy in Japan (2017-2028)
  • Table 59: Site-specific prevalent cases of NETs in Japan (2017-2028)
  • Table 60: Grade-wise prevalent cases of NETs in Japan (2017-2028)
  • Table 61: Stage-wise prevalent cases of NETs in Japan (2017-2028)
  • Table 62: Phase III Drug Analysis
  • Table 63: Phase I/II Drug Analysis
  • Table 64: Phase I/II Drug Analysis
  • Table 65: Phase I/II Drug Analysis
  • Table 66: Phase I/II Drug Analysis
  • Table 67: Lenvatinib, Clinical Trial Description, 2019
  • Table 68: Pasireotide, Clinical Trial Description, 2019
  • Table 69: Spartalizumab, Clinical Trial Description, 2019
  • Table 70: Tirapazamine, Clinical Trial Description, 2019
  • Table 71: PEN-221, Clinical Trial Description, 2019
  • Table 72: Sulfatinib, Clinical Trial Description, 2019
  • Table 73: Ibrutinib, Clinical Trial Description, 2019
  • Table 74: Ramucirumab, Clinical Trial Description, 2019
  • Table 75: ALT 803, Clinical Trial Description, 2019
  • Table 76: Talimogene laherparepvec, Clinical Trial Description, 2019
  • Table 77: Netazepide, Clinical Trial Description, 2019
  • Table 78: 7 Major Market Size of NETs in USD Million (2017-2028)
  • Table 79: The US Market Size of NETs in USD Million (2017-2028)
  • Table 80: Therapies Based market of NETs in the US, in USD Million (2017-2028)
  • Table 81: Market Size of NETs in Germany, in USD Million (2017-2028)
  • Table 82: Therapies Based market of NETs in Germany, in USD Million (2017-2028)
  • Table 83: Market Size of NETs in France, in USD Million (2017-2028)
  • Table 84: Therapies Based market of NETs in France, in USD Million (2017-2028)
  • Table 85: Market Size of NETs in Italy, in USD Million (2017-2028)
  • Table 86: Therapies Based market of NETs in Germany, in USD Million (2017-2028)
  • Table 87: Market Size of NETs in Spain, in USD Million (2017-2028)
  • Table 88: Therapies Based market of NETs in Spain, in USD Million (2017-2028)
  • Table 89: Market Size of NETs in the UK, in USD Million (2017-2028)
  • Table 90: Therapies Based market of NETs in UK, in USD Million (2017-2028)
  • Table 91: Market Size of NETs in Japan, in USD Million (2017-2028)
  • Table 92:Therapies Based market of NETs in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1: Classification of Neuroendocrine Tumors
  • Figure 2: Causes of Neuroendocrine Tumors
  • Figure 3: Targeting critical signaling pathways in NETs
  • Figure 4: Total Prevalent Population of NETs in the 7MM (2017-2028)
  • Figure 5: Total Incident Population of NETs in the 7MM (2017-2028)
  • Figure 6: Total Prevalent cases of NETs in the United States (2017-2028)
  • Figure 7: Total Incident cases of NETs in the United States (2017-2028)
  • Figure 8: Diagnosed prevalent cases of NETs in the United States (2017-2028)
  • Figure 9: Symptom based classification of NETs in the United States (2017-2028)
  • Figure 10: Diagnosed prevalent cases based on Malignancy in the United States (2017-2028)
  • Figure 11: Site-specific prevalent cases of NETs in the United States (2017-2028)
  • Figure 12: Grade-wise prevalent cases of NETs in the United States (2016-2027)
  • Figure 13: Stage-wise prevalent cases of NETs in the United States (2017-2028)
  • Figure 14: Total Prevalent cases of NETs in Germany (2017-2028)
  • Figure 15: Total Incident cases of NETs in Germany (2017-2028)
  • Figure 16: Diagnosed prevalent cases of NETs in Germany (2017-2028)
  • Figure 17: Symptom based classification of NETs in Germany (2017-2028)
  • Figure 18: Diagnosed prevalent cases based on Malignancy in Germany (2017-2028)
  • Figure 19: Site-specific prevalent cases of NETs in Germany (2017-2028)
  • Figure 20: Grade-wise prevalent cases of NETs in Germany (2017-2028)
  • Figure 21: Stage-wise prevalent cases of NETs in Germany (2017-2028)
  • Figure 22: Total Prevalent cases of NETs in the France (2017-2028)
  • Figure 23: Total Incident cases of NETs in the France (2017-2028)
  • Figure 24: Diagnosed prevalent cases of NETs in France (2017-2028)
  • Figure 25: Symptom based classification of NETs in France (2017-2028)
  • Figure 26: Diagnosed prevalent cases based on Malignancy in France (2017-2028)
  • Figure 27: Site-specific prevalent cases of NETs in France (2017-2028)
  • Figure 28: Grade-wise prevalent cases of NETs in France (2017-2028)
  • Figure 29: Stage-wise prevalent cases of NETs in France (2017-2028)
  • Figure 30: Total Prevalent cases of NETs in the Italy (2017-2028)
  • Figure 31: Total Incident cases of NETs in the Italy (2017-2028)
  • Figure 32: Diagnosed prevalent cases of NETs in Italy (2017-2028)
  • Figure 33: Symptom based classification of NETs in Italy (2017-2028)
  • Figure 34: Diagnosed prevalent cases based on Malignancy in Italy (2017-2028)
  • Figure 35: Site-specific prevalent cases of NETs in Italy (2017-2028)
  • Figure 36: Grade-wise prevalent cases of NETs in Italy (2017-2028)
  • Figure 37: Stage-wise prevalent cases of NETs in Italy (2017-2028)
  • Figure 38: Total Prevalent cases of NETs in the Spain (2017-2028)
  • Figure 39: Total Incident cases of NETs in the Spain (2017-2028)
  • Figure 40: Diagnosed prevalent cases of NETs in Spain (2017-2028)
  • Figure 41: Symptom based classification of NETs in Spain (2017-2028)
  • Figure 42: Diagnosed prevalent cases based on Malignancy in Spain (2017-2028)
  • Figure 43: Site-specific prevalent cases of NETs in Spain (2017-2028)
  • Figure 44: Grade-wise prevalent cases of NETs in Spain (2017-2028)
  • Figure 45: Stage-wise prevalent cases of NETs in Spain (2017-2028)
  • Figure 46: Total Prevalent cases of NETs in the UK (2017-2028)
  • Figure 47: Total Incident cases of NETs in the UK (2017-2028)
  • Figure 48: Diagnosed prevalent cases of NETs in the UK (2017-2028)
  • Figure 49: Symptom based classification of NETs in the UK (2017-2028)
  • Figure 50: Diagnosed prevalent cases based on Malignancy in the UK (2017-2028)
  • Figure 51: Site-specific prevalent cases of NETs in the UK (2017-2028)
  • Figure 52: Grade-wise prevalent cases of NETs in the UK (2017-2028)
  • Figure 53: Stage-wise prevalent cases of NETs in the UK (2017-2028)
  • Figure 54: Total Prevalent cases of NETs in Japan (2017-2028)
  • Figure 55: Total Incident cases of NETs in Japan (2017-2028)
  • Figure 56: Diagnosed prevalent cases of NETs in Japan (2017-2028)
  • Figure 57: Symptom based classification of NETs in the Japan (2017-2028)
  • Figure 58: Diagnosed prevalent cases based on Malignancy in Japan (2017-2028)
  • Figure 59: Site-specific prevalent cases of NETs in Japan (2017-2028)
  • Figure 60: Grade-wise prevalent cases of NETs in Japan (2017-2028)
  • Figure 61: Stage-wise prevalent cases of NETs in Japan (2017-2028)
  • Figure 62: Treatment of Neuroendocrine tumors
  • Figure 63: Unmet needs
  • Figure 64: 7 Major Market Size of NETs in USD Million (2017-2028)
  • Figure 65: Market Size of NETs in the US, USD Millions (2017-2028)
  • Figure 66: Therapies Based market of NETs in the US in USD Million (2017-2028)
  • Figure 67: Market Size of NETs in Germany, USD Millions (2017-2028)
  • Figure 68: Therapies Based market of NETs in Germany, in USD Million (2017-2028)
  • Figure 69: Market Size of NETs in France, USD Millions (2017-2028)
  • Figure 70: Therapies Based market of NETs in France, in USD Million (2017-2028)
  • Figure 71: Market Size of NETs in Italy, USD Millions (2017-2028)
  • Figure 72: Therapies Based market of NETs in Italy, in USD Million (2017-2028)
  • Figure 73: Market Size of NETs in Spain, USD Millions (2017-2028)
  • Figure 74: Therapies Based market of NETs in Spain, in USD Million (2017-2028)
  • Figure 75: Market Size of NETs in the UK, USD Millions (2017-2028)
  • Figure 76: Therapies Based market of NETs in the UK, in USD Million (2017-2028)
  • Figure 77: Market Size of NETs in Japan, USD Millions (2017-2028)
  • Figure 78: Therapies Based market of NETs in Japan, in USD Million (2017-2028)
  • Figure 79: Market Drivers
  • Figure 80:Market Barriers
目次
Product Code: DIMI0349

DelveInsight's 'Neuroendocrine Tumors (NETs) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NETs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Neuroendocrine Tumors (NETs) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Neuroendocrine Tumors (NETs) - Disease Understanding and Treatment Algorithm

Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts, but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes causing them to divide uncontrollably and grow into an abnormal tissue mass (tumor).

The DelveInsight Neuroendocrine Tumors (NETs) market report gives the thorough understanding of the Neuroendocrine Tumors by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Neuroendocrine Tumors in the US, Europe and Japan.

Neuroendocrine Tumors Epidemiology

The Neuroendocrine Tumors (NETs) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total incident population, total diagnosed prevalent cases of Neuroendocrine Tumors, symptom based classification, diagnosed prevalent cased based on malignancy, site-specific prevalent cases, grade-specific prevalent cases and stage-specific prevalent cases) scenario of Neuroendocrine Tumors (NETs) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of prevalent cases of Neuroendocrine Tumors (NETs) in 7 MM was found to be 453,191, in the year 2017.

Neuroendocrine Tumors Drug Chapters

This segment of the Neuroendocrine Tumors report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The NETs market forecast provided in the report solely focuses on the market revenue generated by the off-label products (chemotherapy and cytotoxic agents) and targeted therapies that are being used for the treatment of NETs. The somatostatin analogs (SSAs) such octreotide and lanreotide remain the keystone of treatment for most well-differentiated, somatostatin-receptor-expressing metastatic NETs. mTOR inhibitor activity, Angiogenesis inhibitors and Radiolabeled somatostatin analog therapy form the mainstays of NET Therapy. Detailed chapters for upcoming therapies like Azedra (Progenics Pharmaceuticals), Sulfatinib (Hutchison MediPharma), Axitinib (Pfizer), RRx-001 (EpicentRx), Entrectinib (Ignyta), and Carfilzomib (Amgen) have been covered in the report.

Neuroendocrine Tumors Market Outlook

The Neuroendocrine Tumors market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Neuroendocrine Tumors in 7MM was found to be USD 3.57 Billion in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 7MM, the United States accounts for the largest market size of Neuroendocrine tumors, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan

Neuroendocrine Tumors Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Neuroendocrine Tumors Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Neuroendocrine Tumors Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Neuroendocrine Tumors Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Neuroendocrine Tumors market
  • Organize sales and marketing efforts by identifying the best opportunities for Neuroendocrine Tumors market
  • To understand the future market competition in the Neuroendocrine Tumors market.

Table of Contents

1. Key Insights

2. Neuroendocrine Tumors Epidemiology Overview at a Glance

  • 2.1. Market (%) Distribution of Neuroendocrine Tumors in 2017
  • 2.2. Market (%) Distribution of Neuroendocrine Tumors in 2028

3. Disease Background and Overview: Neuroendocrine Tumors (NET)

  • 3.1. Introduction
  • 3.2. Classification of Neuroendocrine Tumors
  • 3.3. Causes
  • 3.4. Risk Factors
  • 3.5. Symptoms
  • 3.6. Pathophysiology
  • 3.7. Diagnosis
    • 3.7.1. Grading of NETs:
    • 3.7.2. Staging of NETs:

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Prevalent Patient Population of NETs
  • 4.3. Total Incident Patient Population of NETs

5. Country Wise-Epidemiology of NETs

  • 5.1. United States
    • 5.1.1. Total Prevalent Cases of NETs in the United States
    • 5.1.2. Total Incident Cases of NETs in the United States
    • 5.1.3. Diagnosed prevalent cases of NETs in the United States
    • 5.1.4. Symptom based classification of NETs
    • 5.1.5. Diagnosed prevalent cases based on Malignancy
    • 5.1.6. Site-specific prevalent cases of NETs
    • 5.1.7. Grade-wise prevalent cases of NETs
    • 5.1.8. Stage-wise prevalent cases of NETs
  • 5.2. EU5 Countries
  • 5.3. Germany
    • 5.3.1. Total Prevalent Cases of NETs in Germany
    • 5.3.2. Total Incident Cases of NETs in Germany
    • 5.3.3. Diagnosed prevalent cases of NETs in Germany
    • 5.3.4. Symptom based classification of NETs
    • 5.3.5. Diagnosed prevalent cases based on Malignancy
    • 5.3.6. Site-specific prevalent cases of NETs
    • 5.3.7. Grade-wise prevalent cases of NETs
    • 5.3.8. Stage-wise prevalent cases of NETs
  • 5.4. France
    • 5.4.1. Total Prevalent Cases of NETs in France
    • 5.4.2. Total Incident Cases of NETs in France
    • 5.4.3. Diagnosed prevalent cases of NETs in France
    • 5.4.4. Symptom based classification of NETs
    • 5.4.5. Diagnosed prevalent cases based on Malignancy
    • 5.4.6. Site-specific prevalent cases of NETs
    • 5.4.7. Grade-wise prevalent cases of NETs
    • 5.4.8. Stage-wise prevalent cases of NETs
  • 5.5. Italy
    • 5.5.1. Total Prevalent Cases of NETs in Italy
    • 5.5.2. Total Incident Cases of NETs in Italy
    • 5.5.3. Diagnosed prevalent cases of NETs in Italy
    • 5.5.4. Symptom based classification of NETs
    • 5.5.5. Diagnosed prevalent cases based on Malignancy
    • 5.5.6. Site-specific prevalent cases of NETs
    • 5.5.7. Grade-wise prevalent cases of NETs
    • 5.5.8. Stage-wise prevalent cases of NETs
  • 5.6. Spain
    • 5.6.1. Total Prevalent Cases of NETs in Spain
    • 5.6.2. Total Incident Cases of NETs in Spain
    • 5.6.3. Diagnosed prevalent cases of NETs in Spain
    • 5.6.4. Symptom based classification of NETs
    • 5.6.5. Diagnosed prevalent cases based on Malignancy
    • 5.6.6. Site-specific prevalent cases of NETs
    • 5.6.7. Grade-wise prevalent cases of NETs
    • 5.6.8. Stage-wise prevalent cases of NETs
  • 5.7. United Kingdom
    • 5.7.1. Total Prevalent Cases of NETs in the UK
    • 5.7.2. Total Incident Cases of NETs in the UK
    • 5.7.3. Diagnosed prevalent cases of NETs in the UK
    • 5.7.4. Symptom based classification of NETs
    • 5.7.5. Diagnosed prevalent cases based on Malignancy
    • 5.7.6. Site-specific prevalent cases of NETs
    • 5.7.7. Grade-wise prevalent cases of NETs
    • 5.7.8. Stage-wise prevalent cases of NETs
  • 5.8. Japan
    • 5.8.1. Total Prevalent Cases of NETs in Japan
    • 5.8.2. Total Incident Cases of NETs in Japan
    • 5.8.3. Diagnosed prevalent cases of NETs in Japan
    • 5.8.4. Symptom based classification of NETs
    • 5.8.5. Diagnosed prevalent cases based on Malignancy
    • 5.8.6. Site-specific prevalent cases of NETs
    • 5.8.7. Grade-wise prevalent cases of NETs
  • 5.9. Stage-wise prevalent cases of NETs

6. Treatment Algorithm

7. Unmet needs

8. Marketed Products

  • 8.1. Afinitor (Everolimus): Novartis
    • 8.1.1. Product Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Other development activities
    • 8.1.5. Safety and Efficacy
    • 8.1.6. Advantages and Disadvantages
    • 8.1.7. Product Profile
  • 8.2. Sutent (Sunitinib Malate): Pfizer
    • 8.2.1. Product Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Other development activities
    • 8.2.5. Safety and Efficacy
    • 8.2.6. Advantages and Disadvantages
    • 8.2.7. Product Profile

To be continued in the report….

9. Emerging Drugs

  • 9.1. Key Cross Competition
  • 9.2. 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen
    • 9.2.1. Product Description
    • 9.2.2. Product Profile
    • 9.2.3. Product Development Activities
    • 9.2.4. Clinical development
    • 9.2.5. Safety and Efficacy
  • 9.3. AMG 479: Amgen
    • 9.3.1. Product Description
    • 9.3.2. Product Profile
    • 9.3.3. Product Development Activities
    • 9.3.4. Clinical Development
    • 9.3.5. Safety and Efficacy
    • 9.3.6. Advantages and Disadvantages
  • 9.4. Anlotinib: Advenchen Laboratories
    • 9.4.1. Product Description
    • 9.4.2. Product Profile
    • 9.4.3. Product Development Activities
    • 9.4.4. Clinical Development

To be continued in the report….

10. Neuroendocrine Tumors: 7 Major Market Analysis

  • 10.1. Key Findings
  • 10.2. Market Size of Neuroendocrine Tumors (NETs) in 7MM

11. Market Outlook by Country

12. The United States: Market Outlook

  • 12.1. United States Market Size
    • 12.1.1. Total Market size of NETs
    • 12.1.2. Market Size by Therapies

13. EU-5 Countries: Market Outlook

  • 13.1. Germany
    • 13.1.1. Total Market size of NETs
    • 13.1.2. Market Size by Therapies
  • 13.2. France
    • 13.2.1. Total Market size of NETs
    • 13.2.2. Market Size by Therapies
  • 13.3. Italy
    • 13.3.1. Total Market size of NETs
    • 13.3.2. Market Size by Therapies
  • 13.4. Spain
    • 13.4.1. Total Market size of NETs
    • 13.4.2. Market Size by Therapies
  • 13.5. United Kingdom
    • 13.5.1. Total Market size of NETs
    • 13.5.2. Market Size by Therapies
  • 13.6. Japan: Market Outlook
    • 13.6.1. Total Market size of NETs
    • 13.6.2. Market Size by Therapies

14. Market Drivers

15. Market Barriers

16. Appendix

  • 16.1. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Back to Top